AstraZeneca CEO Pascal Soriot highlighted that artificial intelligence (AI) is significantly enhancing the company's ability to develop medicines faster and make smarter research decisions. AI tools help identify promising drug targets, optimize molecules to reduce side effects, and improve the chances of success in costly clinical trials. Through partnerships with Tempus AI and Pathos, AstraZeneca uses AI models to analyze clinical and laboratory data, increasing the probability of success in late-stage trials and improving productivity. This advancement could save hundreds of millions of dollars per trial and accelerate innovation across AstraZeneca's drug pipeline.
AstraZeneca reported an 18% year-on-year increase in core earnings per share for Q2 2026, with revenue growth meeting full-year expectations. However, the company faces challenges as its top drug, Farxiga, approaches patent expiry in the U.S. and fac...
The FTSE 100 index gained 40 points to 10,777, supported by a drop in oil prices following a pause in US-Iran strikes and easing retail sector downturn. Retail sales improved in July, though online sales fell sharply, and wholesale volumes stabilized...
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
